Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 6/20 | 0.38 |
| ▸ | APP | P05067 | 5/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2831098 | 1.00 | PTPN1 (0.39) | PTPN1PPARAAPPPPARGMAOB | |
| SCHEMBL2830447 | 1.00 | PTPN1 (0.39) | PTPN1PPARAAPPPPARGMAOB | |
| SCHEMBL2831100 | 1.00 | PTPN1 (0.39) | PTPN1PPARAAPPPPARGMAOB | |
| SCHEMBL2829909 | 1.00 | PTPN1 (0.39) | PTPN1PPARAAPPPPARGMAOB | |
| SCHEMBL2835063 | 1.00 | PTPN1 (0.39) | PTPN1PPARAAPPPPARGMAOB | |
| SCHEMBL2829905 | 1.00 | PTPN1 (0.39) | PTPN1PPARAAPPPPARGMAOB | |
| SCHEMBL18621798 | 0.97 | PTPN1 (0.41) | PTPN1PPARAAPPPPARGMAOB | |
| SCHEMBL16274694 | 0.89 | APP (0.41) | APP | |
| SCHEMBL13360335 | 0.89 | APP (0.41) | APP | |
| SCHEMBL1036532 | 0.88 | PTPN1 (0.38) | PTPN1PPARAAPPPPARGMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392344-B2 | Method for preparing fluorine-18 eluent with adjusted PH, and method for labelling fluorine-18 using same | THE ASAN FOUNDATION (KR) | 2019-08-27 | — | — | US | claimed |
| EP-2575898-B1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGAND | LIFE MOLECULAR IMAGING SA (CH) | 2020-09-30 | — | — | EP | disclosed |
| EP-2575898-B1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGAND | LIFE MOLECULAR IMAGING SA (CH) | 2020-09-30 | — | — | EP | disclosed |
| US-10392344-B2 | Method for preparing fluorine-18 eluent with adjusted PH, and method for labelling fluorine-18 using same | THE ASAN FOUNDATION (KR) | 2019-08-27 | — | — | US | disclosed |
| EP-2579902-B2 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS | PIRAMAL IMAGING SA (CH) | 2019-08-14 | — | — | EP | disclosed |
| EP-2590683-B1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS | PIRAMAL IMAGING SA (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-2590683-B1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS | PIRAMAL IMAGING SA (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-2579902-B1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS | PIRAMAL IMAGING SA (CH) | 2017-07-12 | — | — | EP | disclosed |
| EP-2579902-B1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS | PIRAMAL IMAGING SA (CH) | 2017-07-12 | — | — | EP | disclosed |
| US-9592308-B2 | Method for production of F-18 labeled amyloid beta ligands | PIRAMAL IMAGING SA (CH) | 2017-03-14 | — | — | US | disclosed |
| US-20120184749-A1 | Usage of low to medium-pressure liquid chromatography for the purification of radiotracers | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-19 | — | — | US | disclosed |
| WO-2011151283-A1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151281-A1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151282-A1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGAND | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151282-A1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGAND | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151273-A1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151283-A1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011003591-A1 | USAGE OF LOW TO MEDIUM-PRESSURE LIQUID CHROMATOGRAPHY FOR THE PURIFICATION OF RADIOTRACERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-13 | — | — | WO | disclosed |
| US-20100113763-A1 | METHOD FOR PREPARATION OF ORGANOFLUORO COMPOUNDS IN ALCOHOL SOLVENTS | FUTURECHEM CO., LTD. (KR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113763-A1 | METHOD FOR PREPARATION OF ORGANOFLUORO COMPOUNDS IN ALCOHOL SOLVENTS | FUTURECHEM CO., LTD. (KR) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184749-A1 | Usage of low to medium-pressure liquid chromatography for the purification of radiotracers | TMEM14C, SLC5A7, SLC43A1 | PTPN1 1316/4885PPARA 3419/4885APP 1292/4885 |
| US-10392344-B2 | Method for preparing fluorine-18 eluent with adjusted PH, and method for labelling fluorine-18 using same | PHF8, AFF1, F8 | PTPN1 1435/4885PPARA 3006/4885APP 3973/4885 |
| US-20100113763-A1 | METHOD FOR PREPARATION OF ORGANOFLUORO COMPOUNDS IN ALCOHOL SOLVENTS | AFF1, AFF4, PFAS | PTPN1 2916/4885PPARA 2270/4885APP 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.